William P. Forbes net worth and biography

William Forbes Biography and Net Worth

Executive Vice President, Chief Development Officer of Heron Therapeutics

William Forbes has served as our Executive Vice President, Chief Development Officer since June 2023. Dr. Forbes brings more than thirty years of pharmaceutical product development experience to Heron and has contributed to 14 marketing approvals spanning a diverse range of therapeutic areas in the U.S. and European markets. Prior to joining Heron, Dr. Forbes served as the Chief Development Officer at Trevi Therapeutics, Inc. from 2021 to 2022. From 2016 to 2020, Dr. Forbes served as the President and CEO of Vivelix Pharmaceuticals, Ltd., where he was the founder and responsible for all strategic and operational aspects of the organization. Prior to that, Dr. Forbes served as the Chief Development Officer at Salix Pharmaceuticals, Inc. as the Head of Medical and R&D from 2005 to 2015. Earlier in his career, Dr. Forbes held various positions in clinical research and development at Metabasis Therapeutics, Inc., Otsuka America Pharmaceuticals, Inc., and Glaxo, Inc. Dr. Forbes received his Doctor of Pharmacy degree from Creighton University, and he completed fellowships in cardiovascular research at Creighton Cardiac Center and in clinical research at Glaxo, Inc.

What is William P. Forbes' net worth?: The estimated net worth of William P. Forbes is at least $70.74 thousand as of November 16th, 2023. Mr. Forbes owns 54,000 shares of Heron Therapeutics stock worth more than $70,740 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. Forbes may own. Learn More about William P. Forbes' net worth.
How old is William P. Forbes?: Mr. Forbes is currently 62 years old. There are 4 older executives and no younger executives at Heron Therapeutics. Learn More on William P. Forbes' age.
How do I contact William P. Forbes?: The corporate mailing address for Mr. Forbes and other Heron Therapeutics executives is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. Heron Therapeutics can also be reached via phone at (858) 251-4400 and via email at [email protected]. Learn More on William P. Forbes' contact information.
Has William P. Forbes been buying or selling shares of Heron Therapeutics?: William P. Forbes has not been actively trading shares of Heron Therapeutics in the last ninety days. Most recently, on Thursday, November 16th, William P. Forbes bought 50,000 shares of Heron Therapeutics stock. The stock was acquired at an average cost of $0.94 per share, with a total value of $47,000.00. Following the completion of the transaction, the executive vice president now directly owns 54,000 shares of the company's stock, valued at $50,760. Learn More on William P. Forbes' trading history.
Who are Heron Therapeutics' active insiders?: Heron Therapeutics' insider roster includes Craig Collard (CEO), Ira Duarte (Executive Vice President, Chief Financial Officer), William Forbes (Executive Vice President, Chief Development Officer), Craig Johnson (Director), Kimberly Manhard (EVP), Adam Morgan (Director), and Christian Waage (Director). Learn More on Heron Therapeutics' active insiders.
Are insiders buying or selling shares of Heron Therapeutics?: In the last year, Heron Therapeutics insiders bought shares 2 times. They purchased a total of 4,153,771 shares worth more than $6,230,656.50. The most recent insider tranaction occured on August, 8th when Director Adam Morgan bought 1,766,546 shares worth more than $2,649,819.00. Insiders at Heron Therapeutics own 5.9% of the company. Learn More about insider trades at Heron Therapeutics.
Information on this page was last updated on 8/8/2025.

William P. Forbes Insider Trading History at Heron Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/16/2023	Buy	50,000	$0.94	$47,000.00	54,000

William P. Forbes Buying and Selling Activity at Heron Therapeutics

Heron Therapeutics Company Overview

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Today's Range

Now: $1.31

$1.20

$1.32

50 Day Range

MA: $1.20

$1.06

$1.35

2 Week Range

Now: $1.31

$1.00

$2.68

Volume

2,743,711 shs

Average Volume

1,823,356 shs

Market Capitalization

$240.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.34

William Forbes Biography and Net Worth

What is William P. Forbes' net worth?

How old is William P. Forbes?

How do I contact William P. Forbes?

Has William P. Forbes been buying or selling shares of Heron Therapeutics?

Who are Heron Therapeutics' active insiders?

Are insiders buying or selling shares of Heron Therapeutics?